CLLS
Cellectis S.A.
There isn't enough reported data to score CLLS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CLLS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
CLLS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CLLS PE Valuation
CLLS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CLLS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CLLS's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CLLS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.66 | -$0.07 |
| Q1 2026 | -$0.68 | -$0.05 |
| Q4 2025 | -$0.68 | -$0.28 |
| Q3 2025 | -$0.35 | +$0.65 |
| Q2 2025 | -$0.59 | +$0.49 |
| Q1 2025 | -$0.63 | +$0.38 |
| Q4 2024 | -$0.40 | +$1.25 |
| Q3 2024 | -$1.00 | +$0.71 |
CLLS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CLLS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.2M | -69% |
| Q1 2026 | $5.8M | -46% |
| Q4 2025 | $10.4M | -18% |
| Q3 2025 | $35.2M | +117% |
| Q2 2025 | $16.7M | +107% |
| Q1 2025 | $10.7M | +135% |
| Q4 2024 | $12.7M | +4356% |
| Q3 2024 | $16.2M | +10352% |
CLLS's revenue fell from its 2020 peak and has held roughly level since: $5M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -487% | -430 points |
| Q1 2026 | -467% | -334 points |
| Q4 2025 | -167% | -83 points |
| Q3 2025 | 23% | +89 points |
| Q2 2025 | -57% | +156 points |
| Q1 2025 | -133% | +328 points |
| Q4 2024 | -84% | +10781 points |
| Q3 2024 | -66% | +13270 points |
CLLS's operating margin was −487% last quarter, down 430 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CLLS on profitability, with a higher operating margin.
CLLS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.5M | -$3.9M |
| Q1 2026 | -$15.8M | +$1.7M |
| Q4 2025 | -$11M | -$9.2M |
| Q3 2025 | -$2.8M | +$3.9M |
| Q2 2025 | -$10.6M | -121% |
| Q1 2025 | -$17.6M | +$6M |
| Q4 2024 | -$1.8M | -105% |
| Q3 2024 | -$6.6M | +$10.8M |
CLLS has burned cash in almost every quarter: −$44M over the past year, against −$37M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CLLS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLLS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +120K shares |
| 1 year | +0.3% | +322K shares |
| 3 years | +81% | +45.1M shares |
| 5 years | +121% | +55.2M shares |
| Available history | +137% | +58.2M shares |
CLLS has 101M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $207,000 |
CLLS hasn't bought back shares in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CLLS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CLLS Net Leverage
CLLS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CLLS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 10.3 | Oversold |
CLLS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CLLS PE vs Healthcare Sector
CLLS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CLLS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.21 | 9.9% above |
| 20 week MA | $2.24 | 41% below |
| 50 week MA | $3.19 | 58% below |
| 100 week MA | $2.69 | 51% below |
| 200 week MA | $2.48 | 46% below |
CLLS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CLLS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.9 | $30.4 | +70% |
| 2021 | $30.4 | $8.55 | -72% |
| 2022 | $8.55 | $1.99 | -77% |
| 2023 | $1.99 | $3.08 | +55% |
| 2024 | $3.08 | $1.41 | -54% |
| 2025 | $1.41 | $4.75 | +237% |
| 2026 YTD | $4.75 | $1.33 | -72% |
CLLS's yearly returns have swung widely, from +237% in 2025 to −77% in 2022. It's down 72% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CLLS on returns for 2026, with the stronger performance.